Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Darbepoetin alfa: Phase III

Interim data from the Phase III PREPARE trial in 733 patients showed that Aranesp darbepoetin alfa plus preoperative chemotherapy resulted in no significant improvement in complete tumor response rate at time

Read the full 313 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE